StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Wednesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX stock opened at $7.14 on Wednesday. Brooklyn ImmunoTherapeutics has a one year low of $6.66 and a one year high of $8.31. The stock has a market cap of $420.02 million, a PE ratio of -3.15 and a beta of 4.61. The firm has a 50 day simple moving average of $1.21 and a two-hundred day simple moving average of $1.12.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.